PLATELETBIO Trademark

Trademark Overview


On Friday, October 23, 2020, a trademark application was filed for PLATELETBIO with the United States Patent and Trademark Office. The USPTO has given the PLATELETBIO trademark a serial number of 90273167. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, June 5, 2023. This trademark is owned by Platelet BioGenesis, Inc.. The PLATELETBIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development related to platelets, platelet variants, megakaryocytes, megakaryocytes variants, and products derived from platelets, megakaryocytes or their variants, including, extracellular vesicles or exosomes; Research and development in the field of allogeneic cell therapy, platelet variants, drug delivery and pharmaceutical compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; Biotechnology research; Research in the field of allogeneic cell therapy, platelet variants and pharmaceutical compositions comprising platelet variants; Pharmaceutical research and development; Medical research; Scientific research; Medical and scientific research in the field of allogeneic cell therapy, platelet variants, and phar...
plateletbio

General Information


Serial Number90273167
Word MarkPLATELETBIO
Filing DateFriday, October 23, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, June 5, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkPLATELET BIO
Goods and ServicesResearch and development related to platelets, platelet variants, megakaryocytes, megakaryocytes variants, and products derived from platelets, megakaryocytes or their variants, including, extracellular vesicles or exosomes; Research and development in the field of allogeneic cell therapy, platelet variants, drug delivery and pharmaceutical compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; Biotechnology research; Research in the field of allogeneic cell therapy, platelet variants and pharmaceutical compositions comprising platelet variants; Pharmaceutical research and development; Medical research; Scientific research; Medical and scientific research in the field of allogeneic cell therapy, platelet variants, and pharmaceutical compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; Research and development related to viral vectors and delivery of viral vectors

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, December 11, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePlatelet BioGenesis, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events


Event DateEvent Description
Tuesday, June 6, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, June 5, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, June 5, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, October 17, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, October 17, 2022FINAL REFUSAL E-MAILED
Monday, October 17, 2022FINAL REFUSAL WRITTEN
Thursday, April 14, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 14, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 13, 2022ASSIGNED TO LIE
Thursday, April 7, 2022ASSIGNED TO LIE
Wednesday, April 6, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Saturday, October 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 20, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 20, 2021NON-FINAL ACTION E-MAILED
Tuesday, April 20, 2021NON-FINAL ACTION WRITTEN
Wednesday, March 24, 2021ASSIGNED TO EXAMINER
Friday, December 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 27, 2020NEW APPLICATION ENTERED